These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22571581)

  • 1. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A; Sakai E; Oyama N; Yamamoto T
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
    Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
    J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
    Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
    J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan in systemic sclerosis.
    Heresi GA; Minai OA
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.
    Hettema ME; Zhang D; Bootsma H; Kallenberg CG
    Ann Rheum Dis; 2007 Oct; 66(10):1398-9. PubMed ID: 17881663
    [No Abstract]   [Full Text] [Related]  

  • 8. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
    Varga J
    Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
    Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
    Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
    Ahmadi-Simab K; Lamprecht P; Hellmisch B; Gross WL
    Z Rheumatol; 2004 Dec; 63(6):495-7. PubMed ID: 15605216
    [No Abstract]   [Full Text] [Related]  

  • 13. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
    Shalev L; Langevitz P; Zandman-Goddard G
    Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
    Kurgyis Z; Varga R; Sick I; Lang MU; Ruzicka T; Sárdy M
    Acta Derm Venereol; 2011 Oct; 91(6):716-7. PubMed ID: 21879251
    [No Abstract]   [Full Text] [Related]  

  • 15. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug eruption due to bosentan in a patient with systemic sclerosis.
    Nagai Y; Yamanaka M; Nishimura S; Nakano A; Hasegawa A; Ishikawa O
    Mod Rheumatol; 2006; 16(3):188-90. PubMed ID: 16767560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.
    Giordano N; Puccetti L; Papakostas P; Di Pietra N; Bruni F; Pasqui AL; Acampa M; Bocchi V; Donati V; Voglino M; Fioravanti A; Montella A; Auteri A; Nuti R; Pastorelli M
    Int J Immunopathol Pharmacol; 2010; 23(4):1185-94. PubMed ID: 21244767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
    Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
    Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.